SI3237005T1 - Bispecifična tetravalentna protitelesa in postopki njihove izdelave in uporabe - Google Patents

Bispecifična tetravalentna protitelesa in postopki njihove izdelave in uporabe

Info

Publication number
SI3237005T1
SI3237005T1 SI201532042T SI201532042T SI3237005T1 SI 3237005 T1 SI3237005 T1 SI 3237005T1 SI 201532042 T SI201532042 T SI 201532042T SI 201532042 T SI201532042 T SI 201532042T SI 3237005 T1 SI3237005 T1 SI 3237005T1
Authority
SI
Slovenia
Prior art keywords
making
methods
tetravalent antibodies
bispecific tetravalent
bispecific
Prior art date
Application number
SI201532042T
Other languages
English (en)
Slovenian (sl)
Inventor
Zeren Gao
phil Tan
Brian Kovacevich
Blair Renshaw
Jeffrey Adamo
Nga Sze Amanda Mak
Shi Zhuo
Lan Chen
Yi Zhu
Original Assignee
Systimmune, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systimmune, Inc. filed Critical Systimmune, Inc.
Publication of SI3237005T1 publication Critical patent/SI3237005T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201532042T 2014-12-22 2015-12-19 Bispecifična tetravalentna protitelesa in postopki njihove izdelave in uporabe SI3237005T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462095348P 2014-12-22 2014-12-22
EP15874216.3A EP3237005B1 (en) 2014-12-22 2015-12-19 Bispecific tetravalent antibodies and methods of making and using thereof
PCT/US2015/066951 WO2016106157A1 (en) 2014-12-22 2015-12-19 Bispecific tetravalent antibodies and methods of makiing and using thereof

Publications (1)

Publication Number Publication Date
SI3237005T1 true SI3237005T1 (sl) 2025-02-28

Family

ID=56151464

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201532042T SI3237005T1 (sl) 2014-12-22 2015-12-19 Bispecifična tetravalentna protitelesa in postopki njihove izdelave in uporabe

Country Status (22)

Country Link
US (2) US10717783B2 (enExample)
EP (3) EP3237006B1 (enExample)
JP (2) JP6947639B2 (enExample)
KR (4) KR20250094744A (enExample)
CN (11) CN113105552B (enExample)
AU (1) AU2015369831B2 (enExample)
CA (2) CA3138083A1 (enExample)
DK (1) DK3237005T3 (enExample)
ES (2) ES2962675T3 (enExample)
FI (1) FI3237005T3 (enExample)
HR (1) HRP20241502T1 (enExample)
HU (1) HUE069256T2 (enExample)
IL (3) IL305193A (enExample)
LT (1) LT3237005T (enExample)
NZ (1) NZ732628A (enExample)
PL (1) PL3237005T3 (enExample)
PT (1) PT3237005T (enExample)
RS (1) RS66070B1 (enExample)
SG (1) SG11201704741PA (enExample)
SI (1) SI3237005T1 (enExample)
SM (1) SMT202400477T1 (enExample)
WO (2) WO2016106157A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12428483B2 (en) 2014-12-22 2025-09-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
CN113105552B (zh) * 2014-12-22 2024-09-20 成都百利多特生物药业有限责任公司 双特异性四价抗体及其制造和使用方法
BR112017015136A2 (pt) * 2015-01-14 2018-01-30 Compass Therapeutics Llc polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, construto de ligação ao antígeno imunomodulador multiespecífico, conjugado, composição farmacêutica, método para tratar um indivíduo com câncer, método para inibir ou reduzir o crescimento de câncer, composição, célula, método de fazer um polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, vetor ou conjunto de vetores e kit
CN106632681B (zh) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用
CN108948195B (zh) * 2017-05-23 2022-05-31 胡毅 一种抗egfr/pd-l1双靶向抗体、其制备方法及用途
CN110869389B (zh) * 2017-06-25 2023-07-28 西雅图免疫公司 抗ror1抗体及其制备和使用方法
CN111212658B (zh) * 2017-11-02 2024-05-03 西雅图免疫公司 双特异性抗体及其制备和使用方法
CN111601826B (zh) * 2018-01-15 2023-12-15 南京传奇生物科技有限公司 针对tigit的抗体及其变体
CN108220244A (zh) * 2018-01-18 2018-06-29 东北农业大学 一种含重组人表皮生长因子受体抗体基因的cho细胞株、筛选方法及其生产工艺
CN107974461A (zh) * 2018-01-18 2018-05-01 东北农业大学 一种高效表达anti-hEGFR基因的真核表达载体构建方法
CN112119097B (zh) * 2018-04-13 2021-10-15 艾菲默德有限责任公司 自然杀伤细胞接合抗体融合构建体
AU2019271219A1 (en) * 2018-05-16 2020-11-26 Arbele Limited Composition of bispecific antibodies and method of use thereof
EP3833690B1 (en) * 2018-08-08 2024-03-27 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Recombinant bifunctional protein targeting cd47 and her2
CN110850068B (zh) * 2018-08-21 2023-08-15 上海恒润达生生物科技股份有限公司 一种嵌合抗原受体亲和力检测方法
CN113544144A (zh) * 2018-09-19 2021-10-22 高山免疫科学股份有限公司 变体cd80融合蛋白和相关构建体的方法和用途
WO2020102233A1 (en) * 2018-11-13 2020-05-22 Jn Biosciences Llc Bispecific antibodies for activation of immune cells
AU2020214336A1 (en) * 2019-01-30 2021-09-09 The Wistar Institute Of Anatomy And Biology DNA-encoded bispecific T-cell engagers targeting cancer antigens and methods of use in cancer theraputics
EP4004053A4 (en) * 2019-07-26 2023-10-18 ABL Bio, Inc. BISPECIFIC ANTI-EGFR/ANTI-4-1BB ANTIBODIES AND USE THEREOF
CN120842425A (zh) 2019-08-08 2025-10-28 再生元制药公司 新型抗原结合分子形式
CA3170338A1 (en) * 2020-02-19 2021-08-26 Denali Therapeutics Inc. Engineered anti-her2 bispecific proteins
TWI874613B (zh) * 2020-03-17 2025-03-01 美商西雅圖免疫公司 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
CN111548424A (zh) * 2020-06-05 2020-08-18 上海科弈药业科技有限公司 一种靶向egfr与cd47的多功能融合蛋白及其应用
IL301473A (en) * 2020-09-21 2023-05-01 Systimmune Inc EGFR binding complex and how it is created and used
IL311035A (en) * 2021-08-25 2024-04-01 Systimmune Inc TETRAVALENT BISPIFIC ANTIBODIES TARGETING EGFR AND HER3
WO2023044483A2 (en) * 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
US20240398943A1 (en) * 2021-10-03 2024-12-05 Systimmune, Inc. Methods of treating cancer and the pharmaceutical compositions thereof
CA3237844A1 (en) * 2021-11-15 2023-05-19 Systimmune, Inc. Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
WO2023241480A1 (zh) * 2022-06-13 2023-12-21 三优生物医药(上海)有限公司 抗pd-l1、vegf和egfr三特异性抗体及其应用
JP2025532482A (ja) * 2022-08-31 2025-10-01 システィミューン， インク． Ｅｇｆｒを標的とする二重エピトープ四価抗体
CN116063564A (zh) * 2022-10-08 2023-05-05 盛禾(中国)生物制药有限公司 一种纯化融合蛋白的方法
CN118829655A (zh) * 2023-02-15 2024-10-22 浙江时迈药业有限公司 Egfr和lag3双靶向的双特异性抗体及其用途
CN121443647A (zh) * 2023-07-07 2026-01-30 四川科伦博泰生物医药股份有限公司 EGFR/c-MET双特异性结合蛋白及其用途
WO2025026282A1 (en) * 2023-07-29 2025-02-06 Shanghai Kaijin Biotechnology, Ltd Modified type e multi-specific antibodies
WO2025117871A1 (en) * 2023-11-29 2025-06-05 Systimmune, Inc. Bispecific tetravalent antibody targeting her2 and her3
WO2025140662A1 (en) * 2023-12-29 2025-07-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-egfr/her3 antibodies and uses thereof
TW202540193A (zh) * 2024-03-14 2025-10-16 大陸商珠海普米斯生物科技有限公司 雙特異性抗體、抗體藥物偶聯物及其應用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2200753B (en) 1986-12-23 1991-01-23 Brookes & Gatehouse Speed measurement device
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DK1472275T3 (da) * 2002-02-05 2009-04-14 Genentech Inc Proteinoprensning
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
CN101061140B (zh) * 2004-09-17 2015-07-01 多曼蒂斯有限公司 单价结合cd40l的组合物和应用方法
AU2007260769A1 (en) * 2006-06-14 2007-12-21 Imclone Llc Lyophilized formulations of anti-EGFR antibodies
EP2091975A4 (en) * 2006-11-21 2013-05-22 Univ California ANTIBODIES TO THE EGFR FAMILY, BICE-SPECIFIC ANTIBODIES TO THE EGFR FAMILY AND METHOD FOR THEIR USE
KR20150036824A (ko) * 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
MX2011009810A (es) 2009-03-27 2011-09-30 Zymogenetics Inc Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor.
SG175004A1 (en) 2009-04-02 2011-11-28 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
MX2011010166A (es) 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-3/anti-c-met.
AR078254A1 (es) * 2009-09-01 2011-10-26 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JP5960598B2 (ja) * 2009-11-04 2016-08-02 アフィボディ・アーベー Ｈｅｒ３結合ポリペプチド
AU2011307251A1 (en) * 2010-09-30 2013-02-28 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-HER3 antibodies
WO2012085113A1 (en) 2010-12-23 2012-06-28 Roche Diagnostics Gmbh Binding agent
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
US20140170148A1 (en) * 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2
JP6177231B2 (ja) * 2011-04-20 2017-08-09 ゲンマブ エー／エス Ｈｅｒ２に対する二重特異性抗体
DK2703486T3 (en) * 2011-04-25 2018-05-28 Daiichi Sankyo Co Ltd ANTI-B7-H3 ANTIBODY
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
CN102250247B (zh) 2011-06-15 2013-06-19 常州亚当生物技术有限公司 一种抗vegf/ang2双特异性抗体及其应用
US9718893B2 (en) * 2011-12-19 2017-08-01 Synimmune Gmbh Bispecific antibody molecule
US8961971B2 (en) 2011-12-22 2015-02-24 Development Center For Biotechnology Bispecific T-cell activator antibody
MX2014011500A (es) * 2012-03-27 2014-12-05 Genentech Inc Diagnosticos y tratamientos relacionados a inhibidores her3.
JP6498601B2 (ja) * 2012-07-13 2019-04-10 ザイムワークス，インコーポレイテッド 多価ヘテロ多量体足場設計および構築物
ES2700231T3 (es) * 2012-11-21 2019-02-14 Janssen Biotech Inc Anticuerpos de EGFR/c-Met biespecíficos
CN103333179B (zh) * 2012-12-21 2017-06-16 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
WO2014144357A1 (en) 2013-03-15 2014-09-18 Merck Patent Gmbh Tetravalent bispecific antibodies
US9388243B2 (en) * 2013-05-29 2016-07-12 Samsung Electronics Co., Ltd. Method of target membrane protein depletion
CN113105552B (zh) * 2014-12-22 2024-09-20 成都百利多特生物药业有限责任公司 双特异性四价抗体及其制造和使用方法

Also Published As

Publication number Publication date
PL3237005T3 (pl) 2025-01-27
KR20170091162A (ko) 2017-08-08
IL286835A (en) 2021-10-31
KR102548827B1 (ko) 2023-06-30
KR20250094744A (ko) 2025-06-25
KR102823201B1 (ko) 2025-06-23
JP6947639B2 (ja) 2021-10-13
ES2995733T3 (en) 2025-02-11
CN117467017A (zh) 2024-01-30
IL305193A (en) 2023-10-01
CA2969867A1 (en) 2016-06-30
CN113105551A (zh) 2021-07-13
SMT202400477T1 (it) 2025-01-14
EP3237006A1 (en) 2017-11-01
DK3237005T3 (en) 2024-11-18
IL286835B1 (en) 2023-11-01
EP3237005A1 (en) 2017-11-01
KR20230149328A (ko) 2023-10-26
PT3237005T (pt) 2024-11-18
AU2015369831A1 (en) 2017-06-29
CN113512123B (zh) 2024-10-25
KR20230104988A (ko) 2023-07-11
AU2015369831B2 (en) 2019-07-11
CN113105551B (zh) 2024-10-25
HRP20241502T1 (hr) 2025-01-03
IL252811B (en) 2021-10-31
CN113512120B (zh) 2024-08-02
HUE069256T2 (hu) 2025-02-28
CN113105552B (zh) 2024-09-20
CN113105553B (zh) 2024-09-10
NZ732628A (en) 2019-01-25
ES2962675T3 (es) 2024-03-20
IL252811A0 (en) 2017-08-31
JP7335290B2 (ja) 2023-08-29
CN113512122B (zh) 2024-09-10
CN107206074B (zh) 2023-12-01
IL286835B2 (en) 2024-03-01
WO2016106158A1 (en) 2016-06-30
JP2018509175A (ja) 2018-04-05
CN113105553A (zh) 2021-07-13
US10919977B2 (en) 2021-02-16
CN113105552A (zh) 2021-07-13
EP3237006B1 (en) 2023-08-16
KR102590385B1 (ko) 2023-10-18
US10717783B2 (en) 2020-07-21
CN113150165A (zh) 2021-07-23
CN113512122A (zh) 2021-10-19
CN106659779B (zh) 2021-05-18
EP3237006A4 (en) 2018-05-30
CN113150165B (zh) 2024-09-03
EP4491195A3 (en) 2025-04-02
WO2016106157A1 (en) 2016-06-30
CN107206074A (zh) 2017-09-26
EP3237005B1 (en) 2024-09-18
US20170369587A1 (en) 2017-12-28
LT3237005T (lt) 2024-11-11
CA3138083A1 (en) 2016-06-30
RS66070B1 (sr) 2024-11-29
US20170073418A1 (en) 2017-03-16
FI3237005T3 (fi) 2024-12-02
CN113512121B (zh) 2024-10-25
CA2969867C (en) 2022-01-25
CN113512120A (zh) 2021-10-19
CN106659779A (zh) 2017-05-10
CN113512123A (zh) 2021-10-19
EP4491195A2 (en) 2025-01-15
CN113512121A (zh) 2021-10-19
SG11201704741PA (en) 2017-07-28
JP2021119149A (ja) 2021-08-12
EP3237005A4 (en) 2018-05-23

Similar Documents

Publication Publication Date Title
DK3237005T3 (en) Bispecific tetravalent antibodies and methods of making and using thereof
IL252280A0 (en) Anti pd-1 antibodies and methods of using them
IL251868A0 (en) Anti-tim3 antibodies and methods of use
ZA201703167B (en) Anti-cd79b antibodies and methods of use
ZA201606630B (en) Anti-ox40 antibodies and methods of use
ZA201800315B (en) Anti-jagged1 antibodies and methods of use
IL248399A0 (en) New anti-43rnf antibodies and methods of use
ZA201701674B (en) Novel anti-mfi2 antibodies and methods of use
IL251165A0 (en) Anti-il-1beta antibodies and methods of their use
IL251286A0 (en) Anti-pdgf-b antibodies and methods of use